18-APR-2026 6:11

OPEN STUDIES IRB REPORT

Disease
Site		 Study Study Name Open Date Number of
Active
Institutions		 Number of
Current
IRBs
 
BREAST S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 30-OCT-23 401 136
  S2212 Breast, TNBC, Neoadj Chemo + Pembro 21-JUL-23 430 155
  A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib 06-JAN-21 453 190
  A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab 03-MAY-23 436 187
  A012301 Breast, Early Stg, Tamoxifen 05-FEB-25 433 155
  A012303 Breast, HER2+, Shortened Adj 25-JUL-25 12 7
  MA39 BREAST, Node-Pos, Reg RT vs No Reg RT 30-MAY-18 427 161
  NRGBR009 Breast, EarlyStg, Adjuvant Chemo 31-AUG-23 520 198
 
CCD S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 247 96
  S2417CD Colrec Surv, Follow-up w/ CTAC site 04-AUG-25 157 43
  EAQ221CD Breast, Metastatic, Imp. Adherence 31-OCT-23 140 48
  EAQ222CD CostCOM, Cancer Patients, OOP Cost Com 29-FEB-24 102 43
 
ERLYTX S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 02-DEC-21 266 77
  SN2426 cSCC, IC Met/Inop, Amivantamab v Cetuximab 28-JAN-26 55 14
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 28-AUG-15 292 85
  AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 08-MAY-17 216 116
  EAY191 ComboMATCH 06-MAR-23 348 127
 
GI S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect 16-DEC-19 203 54
  S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs 14-OCT-21 218 72
  S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 06-MAY-24 262 88
  S2433 PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 26-DEC-25 140 42
  A022101 Colorectal, Metastatic, Ablative Tx 10-JAN-23 175 68
  A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo 11-JAN-23 245 100
  CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad 29-FEB-24 177 57
  CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever 05-JUN-23 61 19
  EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab 17-JAN-19 272 82
  EA2192 Panc, APOLLO 29-APR-21 163 76
  EA2222 Colorectal, Stg II-III, Hep Art Infusion 19-OCT-23 116 40
  EA2234 Gastric, all stg, Pac+Sys vs Sys 19-AUG-25 153 49
  NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT 06-MAR-19 88 34
  NRGGI008 Colon, Stg III, Adj Chemo 10-MAR-22 524 199
 
GU S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum 17-SEP-18 345 138
  S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only 16-NOV-20 242 87
  S2210 Pros, High Risk, BRCA, Neoadj Carbo 14-AUG-23 118 35
  S2312 Pros, MCRPC, Cab +/- Carb 03-SEP-24 267 88
  S2427 Blad, MIBC, RT + Pembrolizumab 04-SEP-25 150 65
  A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 12-APR-19 238 80
  A032102 Prostate, All Stg, Precision Diagnostics 11-OCT-24 39 7
  A032103 Urothelial, All Stg, MRD-Based Adj Tx 09-JAN-24 379 149
  A032201 Renal Cell, High-Risk, Pembro+Tiv 05-FEB-25 349 112
  A032302 Prostate, Cast-Sens, Docetaxel 25-SEP-25 12 7
  A032303 Bladder, High Grade, Gem+BCG vs BCG 05-JUN-25 10 2
  CCTG-PR24 Prostate, Unfav, Stereo vs Brachy 11-MAR-24 0 2
  CCTG-PR26 Prostate, Cast Sensitive, Docetax 30-JAN-25 227 77
  EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT 08-SEP-17 49 17
  EA8191 Pros, Local vs Systemic Thrpy 08-OCT-20 174 56
  EA8192 Blad, High Grade UTUC, Durv + Chemo 06-MAY-21 149 50
  NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy 30-JUN-22 297 92
  NRGGU013 Prostate, High-Risk, Five Fraction Radiation 13-NOV-23 345 113
 
LEUK S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O 14-DEC-20 276 94
  A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 01-JUN-17 286 87
  A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 16-NOV-18 169 46
  EA9213 T-ALL, dara-hyal for chemo refractory MRD 16-JUN-22 114 39
  MM1OA-EA02 MyeloMATCH: AML, New Dx, Ven+HMA 06-JUN-24 303 102
  MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 01-APR-25 213 61
  MM1YA-CTG01 MyeloMATCH: AML, New Dx w/ Int Risk, Ven+Chem 18-JUL-24 37 7
  MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental 16-MAY-24 303 106
  MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 16-MAY-24 366 139
 
LUNG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab 28-APR-25 349 112
  S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 03-APR-23 343 109
  S1900J MET Amplification: Amivantamab Hyaluronidase 27-SEP-24 242 80
  S1900K MET Exon 14: Tepotinib +/- Ramucirumab 18-DEC-23 271 89
  S2402 NSCLC, All Stg, Periop Vs Adj Tx 11-DEC-24 139 62
  S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx 08-SEP-25 229 66
  S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance 14-MAR-25 278 83
  A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO 03-JUN-20 433 165
  A082002 Lung, Adv, Systemic Tx +/- SBRT 21-DEC-21 257 74
  EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 05-APR-18 90 33
  EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 22-OCT-20 227 82
  EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno 15-FEB-24 215 80
  LUNGMAP NSCLC, Adv, Master 28-JAN-19 472 183
  NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo 10-MAY-23 332 129
 
LYMPH S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 23-FEB-23 133 43
  S2308 FL, LTB, Mosunetuzumab vs Rituximab 01-AUG-24 256 88
  A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P 30-JUL-21 201 78
  A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub 08-SEP-23 226 76
  AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy 28-APR-23 294 127
  EA4231 Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev 24-JUN-25 35 3
  EA4232 Lymph, Peri T Cell, Auto Stem 30-JAN-25 48 11
 
MELAN A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo 01-JUN-22 117 52
 
MMYEL S1803 MM, Maintenance, Len vs Len/Dara 27-JUN-19 322 115
  S2005 WM, Prev. Untreated, I/R or Z v V/R 24-JUN-21 141 31
  S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 30-MAY-23 273 86
  S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 01-DEC-23 174 50
  EAA173 MYEL, SMM, Rd +/- Daratumumab 30-APR-19 259 94
  EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 27-OCT-20 247 82
 
MMYL A062102 MMYL, All Stg, Iberdomide Tx 04-APR-24 74 25
 
MULT S2101 Melan or HNSCC, Adv, Cabo + Nivo 14-OCT-22 195 65
 
OTHER A072201 Glioblastoma, Recurrent, Block vs SOC 03-SEP-24 298 106
  A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab 18-SEP-23 6 3
  A092205 HN Squamous, Rec/Metas, Pem vs Pem+Cet 21-NOV-24 143 55
  A151804 irAEs, National Biorepository to Adv Studies 31-JAN-20 157 72
  CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx 29-SEP-22 85 21
  CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy 25-MAY-18 116 44
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 254 74
  EA3191 HN, High Risk HNSCC, Adj +/- Pembro 08-JAN-21 218 68
  EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox 13-JUN-24 180 67
  NRG-HN014 HN, Stg III/IV, Neoadj vs SOC 20-DEC-24 59 19
  NRGBN003 Mening, Grd II, Observation vs Irradiation 14-JUN-17 305 83
  NRGBN013 Brain, Intact Metas, SRS vs FSRS 28-AUG-24 299 115
  NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE 12-AUG-22 333 129
  NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx 16-APR-24 162 60
  NRGGY036 Ovary, All Stg, Olaparib +/- Bevac 16-JAN-25 327 120
  NRGHN006 HN, Erly Stg, Biopsy vs Dissection 08-JUL-20 259 78
  NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN 27-OCT-21 302 105
  NRGHN010 HER2+ SGC, T-DM1 vs TH 30-SEP-22 145 49
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 387 110
 
PEOLC S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 227 79
 
PREV A212102 Blind Ref Set for Multicancer Early Detection 01-AUG-22 221 94
  EA2185 Panc, Impact of Panc Cyst Surveillance 16-JAN-20 170 77
  NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs 06-OCT-21 196 82
  NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO 23-JUN-20 397 143
 
SXQOL S2013 I-CHECKIT: ICI toxicity risk prediction study 16-AUG-21 245 109
  S2205 ICE COMPRESS: Reduction of CIPN from Taxanes 16-MAR-23 17 30
  A211901 Cancer survivors who smoke, txt cessation 01-DEC-21 117 51
  ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis 14-AUG-23 179 68
  NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction 19-SEP-22 68 25
  NRGCC011 Breast, Survivors, Cog Training 02-FEB-24 282 101
  NRGCC015 E-Mindfulness After Breast Cancer 12-JUN-25 292 87